PubMed Health⌕ Search

Biomedical subjects

K L Vosti

Publications and source records attributed to K L Vosti.

49 records · Page 3Linked to original sources
PubMed1968

Production of and sensitivity to colicins among serologically classified strains of Escherichia coli.

A significant proportion of 242 serologically classified strains of Escherichia coli of human origin produced colicins (33%) or were inhibited by one or more of six standard colicins (57%). The most common colicins identified were E1, I, and B; colicins B and V had greatest range of activity. Generally, neither the production of, nor sensitivity to, individual colicins was restricted to strains of a single serogroup. The coexistence of strains of one serogroup that were sensitive to the action of a colicin produced by strains of another serogroup was encountered among 2 of 21 fecal specimens containing strains of multiple serogroups. The production of colicins was not a major determinant in the acquistion of, or subsequent changes in, strains of E. coli in the feces of 10 newborn infants.

Bacteriological Techniques↗
PubMed1965

Cephalothin. Its in vitro antibacterial spectrum as studied in a diagnostic laboratory.

Of 655 bacterial strains isolated in a routine clinical diagnostic laboratory, 564 (86 per cent) were found sensitive to cephalothin by disk sensitivity test. However, the fraction of sensitive Gram-negative bacilli and enterococci declined sharply at concentrations approximating those obtained in serum after the usual recommended dosages. Gram-positive bacteria remained sensitive throughout the entire range of testing concentrations. Unless very high dosages are used, cephalothin cannot be considered a broad-spectrum antibacterial agent for use while cultures are pending. Even with very high dosages all strains of Pseudomonas spp. and significant fractions of other Gram-negative bacillary species remain resistant to cephalothin. If used alone, the high potency cephalothin disk may yield inadequate information and should be supplemented by a lower potency disk, standardized measurements of zone diameters, or a screening plate.

Cephalothin↗
PubMedDate not supplied

Response to pneumococcal vaccine among children with Hodgkin's disease.

Nineteen children with Hodgkin's disease were immuized with dodecavalent pneumococcal vaccine; the efficacy of vaccination, the duration of response, and the significance of the time of immunization in relation to splenectomy and subsequent irradiation and chemotherapy were investigated. Eight children were immunized before splenectomy, and 11 were immunized after splenectomy, irradiation, and chemotherapy. All children were irradiated, and all but two received chemotherapy with MOPP (nitrogen mustard, vincristine sulfate, procarbazine, and prednisone). Sera were assayed for antibodies to the 12 polysaccharide types in the vaccine. The group of children immunized before splenectomy had a significant antibody response to 67% of the antigens tested, whereas the group immunized after splenectomy responded to 40% of the antigens (P less than 0.0001). The duration of response was variable. Pneumococcal vaccine was more likely to provoke an immunologic response if administered before splenectomy than if administered after splenectomy, irradiation, and chemotherapy; however, the response was not uniform. A response to one antigen did not necessarily imply a response to other antigens. In the absence of a readily available assay to determine a protective antibody response, one cannot rely on the vaccine as the sole means of preventing pneumococcal infections in asplenic children with Hodgkin's disease.

Adolescent↗
PubMedDate not supplied

Open trial of imipenem/cilastatin therapy for serious bacterial infections.

Imipenem is a new beta-lactam antibiotic with a wide spectrum of activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The efficacy and toxicity of this drug, when administered parenterally in combination with the dehydropeptidase I inhibitor cilastatin, were studied in 41 hospitalized patients with serious infections. Clinical cure was achieved in 26 (79%) of the 33 patients who could be evaluated and microbiologic cure in 23 (85%) of the 27 patients who could be evaluated. Adverse clinical or laboratory reactions were observed in seven (17%) of the 41 patients. Thus, imipenem/cilastatin was highly effective in the treatment of a wide variety of serious bacterial infections.

Adult↗